[Editorial] Cancer risk paradox: grand plans fall short?

Most oncology conferences now routinely host sessions on precision oncology. This year's Annual Meeting of the American Association for Cancer Research (AACR) in Washington, DC, USA (April 1–5, 2017) was no exception, and last year's meeting saw the launch of the ambitious Cancer Moonshot programme, which laid out plans to accelerate two-fold the transition of genetic and immunological findings from laboratories to the clinic—a goal formally recognised when the US Senate approved dedicated funding via the 21st Century Cures Act.

http://ift.tt/2p6897D